The creation of personal and individualized anti-cancer treatments has been a major goal in the progression of cancer discovery as evident by the continuous research efforts in genetics and population based PK/PD studies. In this paper we use our clinical decision support tool, called ChemoDSS, to evaluate the effectiveness of three treatments recommended by the NCCN guidelines for ovarian cancer using pre-clinical data from the literature. In particular, we analyze the treatments of PC (i.e., Paclitaxel and Cispaltin), DC (i.e., Docetaxel and Carboplatin), and PBC (i.e., Paclitaxel, Bevacizumab, and Carboplatin). Our in silico analysis of the ovarian cancer treatments shows that PC was the most effective regimen for treating ovarian cancer compared to DC and PBC, which is consistent with literature findings. We demonstrate that we can successfully evaluate the effectiveness of the selected ovarian cancer treatment regimens using ChemoDSS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1109/EMBC.2014.6944363 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
UBE2J1 is identified as a novel plasma cell-related gene involved in the prognosis of high-grade serous ovarian cancer.
J Transl Med
January 2025
Department of Gynecology, The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Shijiazhuang, 050000, Hebei, China.
Background: Immune cells within tumor tissues play important roles in remodeling the tumor microenvironment, thus affecting tumor progression and the therapeutic response. The current study was designed to identify key markers of plasma cells and explore their role in high-grade serous ovarian cancer (HGSOC).
Methods: We utilized single-cell sequencing data from the Gene Expression Omnibus (GEO) database to identify key immune cell types within HGSOC tissues and to extract related markers via the Seurat package.
Correction: Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.
J Ovarian Res
January 2025
Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
Sempervirine inhibits proliferation, invasion and metastasis of ovarian cancer cells and induces ultrastructural changes in vivo.
J Ovarian Res
January 2025
Department of Obstetrics and Gynecology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China.
Ovarian cancer is one of the deadliest gynecological malignancies due to its late diagnosis and easy recurrence. Therefore, it is urgent to develop novel therapeutics for ovarian cancer treatment. In this study, we evaluated the anti-ovarian cancer effects of sempervirine in vitro and in vivo.
View Article and Find Full Text PDFExploring the mechanism of Schisandra rubriflora in the treatment of polycystic ovary syndrome based on network pharmacology and molecular docking.
J Ovarian Res
January 2025
Department of Reproductive Medicine Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China.
Background: Polycystic ovary syndrome (PCOS) is an endocrine disease associated with reproductive and metabolic abnormalities. The aim of this study was to elucidate the effects of Schisandra rubriflora (S. rubriflora) on PCOS and its related mechanisms using network pharmacology, molecular docking and in vitro experiments.
View Article and Find Full Text PDFFactors influencing role preferences in decision-making of healthy women with BRCA1/2 pathogenic variants: subanalysis from a randomised controlled decision coaching trial.
BMC Cancer
January 2025
Faculty of Medicine, University of Cologne and Institute for Health Economics and Clinical Epidemiology, University Hospital Cologne, Cologne, Germany.
Background: Patients who actively engage in their medical decision-making processes can experience better health outcomes. This exploratory study aimed to identify predictors of preferred and actual roles in decision-making in healthy women with BRCA1/2 pathogenic variants (PVs).
Methods: Women with BRCA1/2 PVs without a history of breast and/or ovarian cancer were recruited in six centres across Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!